Everything below concerns aspartimide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, solid | Approximately -20 C | Sealed, desiccated, protected from light |
| Typical identity method | Electrospray mass spectrometry | Protonated ion expected near 391 |
| Typical purity method | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Common synonyms | Epithalon, epithalone, AEDG | Spelling variants appear in supplier catalogues |
| Solution stability | Days at 2-8 C | Hydrolysis and deamidation limit shelf life |
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
Typical storage for the lyophilized powder is −20 °C or lower, in a sealed container protected from light and moisture. Hygroscopic material should be allowed to equilibrate to room temperature before the vial is opened, which limits condensation on the contents. Working solutions are commonly divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Dilute solutions are more prone to adsorption onto plastic surfaces and to loss during filtration, so procedures that minimize transfers and use low-binding labware are preferable.
Dissolution is usually performed in water or a suitable aqueous buffer, and the resulting liquid is divided into single-use portions before freezing. Freeze-thaw cycling is a recognised source of loss for short peptides, since each cycle can encourage aggregation or adsorption onto container walls. Working solutions are generally kept cold and used within a short window, although published stability data specific to epitalon are thin. Containers should be marked with concentration and date, and solutions examined for cloudiness before use.
Identity is normally established by reversed-phase high-performance liquid chromatography combined with mass spectrometry, a pairing that separates components and confirms molecular mass at once. Purity is quoted as a percentage from the chromatogram, and figures above ninety-five percent are a frequent commercial specification. Amino acid analysis or sequencing supplies further confirmation when required. Because many short peptides behave similarly under chromatography, retention time alone does not establish sequence; the mass measurement is what separates one tetrapeptide from another, and certificates should report both.
Short peptides such as AEDG are normally supplied as a freeze-dried solid and are kept dry, cold, and shielded from light. Holding at minus twenty degrees Celsius is common for the long term, while a refrigerator suffices for brief periods before use. The material takes up moisture to some degree, so containers should stay sealed and be allowed to reach room temperature before opening, which limits condensation on the contents. Repeated warming and cooling of a single container is discouraged because it admits water and can lower the amount of intact peptide.
Joseph Priestley (1733–1804) was an English polymath who discovered nitrous oxide, nitric oxide, ammonia, hydrogen chloride, and (along with Carl Wilhelm Scheele and Antoine Lavoisier) oxygen. Beginning in 1775, Priestley published his research in Experiments and Observations on Different Kinds of Air, a six-volume work. The recent discoveries about these and other gases stimulated a great deal of interest in the European scientific community. Thomas Beddoes (1760–1808) was an English philosopher, physician and teacher of medicine, and like his older colleague Priestley, was also a member of the Lunar Society of Birmingham. With an eye toward making further advances in this new science as well as offering treatment for diseases previously thought to be untreatable (such as asthma and tuberculosis), Beddoes founded the Pneumatic Institution for inhalation gas therapy in 1798 at Dowry Square in Clifton, Bristol. Beddoes employed chemist and physicist Humphry Davy (1778–1829) as superintendent of the institute, and engineer James Watt (1736–1819) to help manufacture the gases. Other members of the Lunar Society such as Erasmus Darwin and Josiah Wedgwood were also actively involved with the institute. During the course of his research at the Pneumatic Institution, Davy discovered the anesthetic properties of nitrous oxide. Davy, who coined the term "laughing gas" for nitrous oxide, published his findings the following year in the now-classic treatise, Researches, chemical and philosophical–chiefly concerning nitrous oxide or dephlogisticated nitrous air, and its respiration.
Theodor W. Adorno (; German: [ˈteːodoːɐ̯ aˈdɔʁno] ; born Theodor Ludwig Wiesengrund; 11 September 1903 – 6 August 1969) was a German philosopher, cultural, and music critic. He was a leading member of the Frankfurt School of critical theory, whose work has come to be associated with thinkers such as Ernst Bloch, Walter Benjamin, Max Horkheimer, Erich Fromm, and Herbert Marcuse, for whom the works of Sigmund Freud, Karl Marx, and G. W. F. Hegel were essential to a critique of modern society. As a critic of both fascism and what he called the culture industry, he authored numerous works—such as Dialectic of Enlightenment (1947), Minima Moralia (1951), and Negative Dialectics (1966)—that strongly influenced the European New Left. In an intellectual climate shaped by existentialism and logical positivism, Adorno developed a dialectical conception of history and philosophy that challenged the foundations of both, anticipating the divide that would later emerge between the analytic and continental traditions. As a classically trained musician, Adorno studied composition with Alban Berg of the Second Viennese School, influenced by his early admiration for the music of Arnold Schoenberg. Adorno's commitment to avant-garde music formed the backdrop of his subsequent writings and led to his collaboration with Thomas Mann on the latter's novel Doctor Faustus (1947), while the two men lived in California as exiles during the Second World War.
=== MeSH D12.644.456 – oligopeptides === MeSH D12.644.456.050 – amanitins MeSH D12.644.456.073 – angiotensins MeSH D12.644.456.073.021 – angiotensin i MeSH D12.644.456.073.041 – angiotensin ii MeSH D12.644.456.073.041.050 – angiotensin amide MeSH D12.644.456.073.041.800 – saralasin MeSH D12.644.456.073.041.815 – 1-sarcosine-8-isoleucine angiotensin ii MeSH D12.644.456.073.055 – angiotensin iii MeSH D12.644.456.073.070 – angiotensinogen MeSH D12.644.456.120 – antipain MeSH D12.644.456.193 – bradykinin MeSH D12.644.456.193.400 – kallidin MeSH D12.644.456.241 – caerulein MeSH D12.644.456.270 – chalones MeSH D12.644.456.300 – delta sleep-inducing peptide MeSH D12.644.456.345 – dipeptides MeSH D12.644.456.345.159 – anserine MeSH D12.644.456.345.190 – aspartame MeSH D12.644.456.345.331 – carnosine MeSH D12.644.456.345.360 – enalapril MeSH D12.644.456.345.360.300 – enalaprilat MeSH D12.644.456.345.575 – glycylglycine MeSH D12.644.456.345.600 – lisinopril MeSH D12.644.456.400 – n-formylmethionine leucyl-phenylalanine MeSH D12.644.456.448 – glutathione MeSH D12.644.456.448.500 – glutathione disulfide MeSH D12.644.456.448.750 – s-nitrosoglutathione MeSH D12.644.456.460 – gonadorelin MeSH D12.644.456.460.150 – buserelin MeSH D12.644.456.460.315 – goserelin MeSH D12.644.456.460.480 – leuprolide MeSH D12.644.456.460.600 – nafarelin MeSH D12.644.456.460.800 – triptorelin MeSH D12.644.456.580 – leupeptins MeSH D12.644.456.650 – netropsin MeSH D12.644.456.716 – pentagastrin MeSH D12.644.456.724 – pepstatins MeSH D12.644.456.726 – peptichemio MeSH D12.644.456.729 – peptide t MeSH D12.644.456.735 – phalloidine MeSH D12.644.456.745 – thyrotropin-releasing hormone MeSH D12.644.456.800 – tachykinins MeSH D12.644.456.800.354 – eledoisin MeSH D12.644.456.800.475 – kassinin MeSH D12.644.456.800.500 – neurokinin a MeSH D12.644.456.800.550 – neurokinin b MeSH D12.644.456.800.745 – physalaemin MeSH D12.644.456.800.866 – substance p MeSH D12.644.456.805 – technetium tc 99m mertiatide MeSH D12.644.456.810 – teprotide MeSH D12.644.456.830 – tetragastrin MeSH D12.644.456.835 – thymic factor, circulating MeSH D12.644.456.840 – tuftsin MeSH D12.644.456.925 – vasopressins MeSH D12.644.456.925.100 – argipressin MeSH D12.644.456.925.100.250 – deamino arginine vasopressin MeSH D12.644.456.925.325 – felypressin MeSH D12.644.456.925.480 – lypressin MeSH D12.644.456.925.700 – ornipressin MeSH D12.644.456.925.730 – oxytocin MeSH D12.644.456.925.940 – vasotocin
=== Wilson's disease === Penicillamine was developed to treat Wilson's disease, a rare hereditary disease that can lead to a fatal accumulation of copper in the body. This drug was later found to be effective in treating arthritis. Bis-choline tetrathiomolybdate is currently under investigation as a therapy against Wilson's disease.
This appeared to be dependent on proteasomal degradation of FoxM1, as expression of a FoxM1 mutant lacking a degron rescued the effects of OGT knockdown. FoxM1 was found not to be directly modified by O-GlcNAc, suggesting that hyper-O-GlcNAcylation of FoxM1 regulators impairs FoxM1 degradation. Targeting OGT also lowered levels of FoxM1-regulated proteins associated with cancer invasion and metastasis (MMP-2 & MMP-9), and angiogenesis (VEGF). O-GlcNAc modification of cofilin S108 has also been reported to be important for breast cancer cell invasion by regulating cofilin subcellular localization in invadopodia.
Sources: en.wikipedia.org
5-HT1B receptor, also coupled to Gi/o proteins, mediates serotonin-dependent inhibition of dopaminergic neuron excitability and modulate the balance between reward approach and behavioral inhibition. Chronic stress-induced elevation of 5-HT1B expression in these accumbens neurons paradoxically increases sensitivity to dopamine suppression and amplifies the anhedonic phenotype despite the simultaneous reduction in baseline serotonin availability. Collectively, under conditions of chronic stress, sustained KOR-mediated suppression could result in reduced release and enhanced uptake of serotonin, leading to diminished activation of postsynaptic serotonergic receptors in mesocorticolimbic ("hedonic") circuits and contributing to the dysphoric and anhedonic states associated with sustained KOR activation.
Publication of the Inquiry and the subsequent energetic promulgation by Jenner of the idea of vaccination with a virus other than variola virus constituted a watershed in the control of smallpox for which he, more than anyone else deserves the credit. As vaccination spread, some European countries made it compulsory. Concern about its safety led to opposition and then repeal of legislation in some instances. Compulsory infant vaccination was introduced in England by the Vaccination Act 1853 (16 & 17 Vict. c. 100). By 1871, parents could be fined for non-compliance, and then imprisoned for non-payment. This intensified opposition, and the Vaccination Act 1898 (61 & 62 Vict. c. 49) introduced a conscience clause. This allowed exemption on production of a certificate of conscientious objection signed by two magistrates. Such certificates were not always easily obtained and a further act in 1907 allowed exemption by a statutory declaration which could not be refused. Although theoretically still compulsory, the Vaccination Act 1907 (7 Edw. 7. c. 31) effectively marked the end of compulsory infant vaccination in England.
== Early life and education == King was born in 1934 in an army family. Since childhood, King enjoyed hiking and camping. He graduated from Episcopal High School in Alexandria, Virginia. He received a B.E. in chemical engineering from Yale University in 1956. He then entered Massachusetts Institute of Technology, where he received S.M. in chemical engineering in 1958 and Sc.D. in chemical engineering in 1960, under the supervision of J. Edward Vivian.
De Novo Biosynthesis Pathway: Convert NAD+ from tryptophan through the kynurenine pathway. Preiss-Handler Pathway: These include nicotinamide nucleotide transhydrogenase, which synthesizes NAD+ from nicotinic acid (NA). Salvage Pathway: biotransforms NAM, NR, and NMN into NAD+.
In the early stages of the Syrian civil war, when Assad was reported as "perpetrating massacres of his own people", Galloway said Assad's opponents were "trying to pressure Syria and President Assad because of the good things that he did, such as supporting Palestinian and Lebanese resistance and rejecting to surrender to Israel".
Sources: en.wikipedia.org
The solid is kept cold, dry and dark, typically at minus twenty degrees Celsius, in a sealed container with desiccant. Dissolved material is kept refrigerated and used promptly. Freezing and thawing a solution repeatedly is avoided because it accelerates degradation.
Reversed-phase chromatography with ultraviolet detection gives a purity percentage, while mass spectrometry confirms identity. Amino acid analysis checks the residue composition. Buyers typically request a certificate of analysis showing these measurements for the specific lot.
It is not authorised as a medicine in the United States or the European Union. Material is sold there as a research chemical or cosmetic ingredient. Some related short peptides are registered drugs in Russia, which is a distinct national situation rather than a general approval.
Mass spectrometry provides the identity check, because the observed mass is compared with the theoretical mass of the AEDG sequence. Chromatography separates and quantifies impurities but does not by itself prove which peptide is present. The two techniques are normally used together.